Page last updated: 2024-12-08

5-fluorouridine 5'-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-fluorouridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having 5-fluorouracil as the pyrimidine component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID150856
CHEMBL ID474163
CHEBI ID40101
SCHEMBL ID465109
MeSH IDM0066446

Synonyms (26)

Synonym
796-66-7
5-fluorouridine monophosphate
5-fluoro-uridine-5'-monophosphate
5-fluorouridylate
{[(2r,3s,4r,5r)-5-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
bdbm27943
uridine derivative, 39
[(2r,3s,4r,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
chebi:40101 ,
5-fluoro-ump
CHEMBL474163
5-fluorouridine 5'-phosphate
5-fluorouridylic acid
fump-5'
unii-bmw6rnk254
bmw6rnk254 ,
5'-uridylic acid, 5-fluoro-
fosfluoridine
5-fluorouridine 5'-monophosphate
SCHEMBL465109
5-fluorouridine 5'-(dihydrogen phosphate)
5-f-ump
Q27120389
5-fluoro-4-hydroxy-1-(5-o-phosphonopentofuranosyl)pyrimidin-2(1h)-one
DTXSID601000617
((2r,3s,4r,5r)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The possibility of decreasing the gastrointestinal (GI) toxic effects of 5-fluorouracil (5-FU) on the digestive tract such as its injury of cells and induction of diarrhea, without reducing its antitumor activity, was investigated in rats."( Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.
Fukushima, M; Shimamoto, Y; Shirasaka, T, 1993
)
0.29
" Empty liposomes incurred no toxic effects on the retina."( Retinal toxicity of the antimetabolite 5-fluorouridine 5'-monophosphate administered intravitreally using multivesicular liposomes.
Assil, KK; Freeman, WR; Gariano, RF; Munguia, D; Weinreb, RN; Wiley, CA, 1994
)
0.29
" Thymidine promotes microbial conversion of the prodrug FUdR into toxic 5-fluorouridine-5'-monophosphate (FUMP), leading to enhanced host death associated with mitochondrial RNA and DNA depletion, and lethal activation of autophagy."( Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion.
Benjamin, SB; Drangowska-Way, A; Hilzendeger, MA; Joshi, C; Ke, W; Lewis, N; Locasale, J; Mony, VK; O'Rourke, EJ; Patti, GJ; Saba, JA; Yao, CH; Zhang, S, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidine ribonucleoside 5'-monophosphate
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Orotidine 5'-phosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKi462.66671.10003.65006.2000AID1798852; AID393512
Uridine 5'-monophosphate synthaseHomo sapiens (human)Ki280.33330.01700.01700.0170AID1798852; AID393514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
'de novo' pyrimidine nucleobase biosynthetic processUridine 5'-monophosphate synthaseHomo sapiens (human)
UMP biosynthetic processUridine 5'-monophosphate synthaseHomo sapiens (human)
UDP biosynthetic processUridine 5'-monophosphate synthaseHomo sapiens (human)
female pregnancyUridine 5'-monophosphate synthaseHomo sapiens (human)
lactationUridine 5'-monophosphate synthaseHomo sapiens (human)
'de novo' UMP biosynthetic processUridine 5'-monophosphate synthaseHomo sapiens (human)
cellular response to xenobiotic stimulusUridine 5'-monophosphate synthaseHomo sapiens (human)
pyrimidine nucleobase biosynthetic processUridine 5'-monophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
orotate phosphoribosyltransferase activityUridine 5'-monophosphate synthaseHomo sapiens (human)
orotidine-5'-phosphate decarboxylase activityUridine 5'-monophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleusUridine 5'-monophosphate synthaseHomo sapiens (human)
cytoplasmUridine 5'-monophosphate synthaseHomo sapiens (human)
cytosolUridine 5'-monophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID393514Reversible inhibition of human ODCase2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID393512Reversible inhibition of Methanobacterium thermoautotrophicum ODCase2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
AID1798852Enzyme Inhibition Assay from Article 10.1021/jm801224t: \\Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.\\2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (54.17)18.7374
1990's7 (29.17)18.2507
2000's2 (8.33)29.6817
2010's1 (4.17)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.07 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]